Parmax Pharma Ltd vs CIPLA LTD
A side-by-side comparison of Parmax Pharma Ltd (540359) and CIPLA LTD (CIPLA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads 540359 vs CIPLA on 9 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability13
- Growth01
- Size & financial health13
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
CIPLA takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
CIPLA takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is expected to give good quarter"]
- − ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of -14.3% over past five years.", "Promoter holding is low: 30.8%", "Debtor days have increased from 57.4 to 95.2 days."]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.